Transforming the early detection
and intervention of cancer
Our Unique Biomarker
OncAlert Labs develops tests based on patented technology that detects specific protein markers known to indicate an elevated risk for early stage cancers, even prior to observation of visual or physical symptoms.
Actionable Insights for Earlier Oral Cancer
OraMark’s oral rinse collection method is easy to administer and non-invasive for the patient. The test delivers accurate, quantitative results that help optimize patient management and surveillance both pre- and post-biopsy.
Featured News and Events
May 10, 2017 |
Vigilant Biosciences Announces Commencement of FDA Studies for OncAlert® Cancer Test
Company begins drive toward FDA clearance of first and only test to detect a tumor-initiating stem cell-associated biomarker for oral and oropharyngeal cancer
May 05, 2017 |
eMerge Americas
June 12 – 13, 2017
May 03, 2017 | Real Health Magazine
The Word of Mouth on Oral Cancer
Nearly 50,000 people are diagnosed with oral cancer in the U.S. each year—and that number continues to grow, particularly among certain segments of the population.